RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy) gene analysis, targeted sequence analysis (eg, exons 3-8)
CPT4 code
Name of the Procedure:
RUNX1 (Runt Related Transcription Factor 1) Gene Analysis, Targeted Sequence Analysis (e.g., exons 3-8)
Summary
This procedure involves analyzing specific parts of the RUNX1 gene to identify mutations or abnormalities. It focuses specifically on exons 3-8, which are common regions for variations that can be linked to certain blood disorders and cancers.
Purpose
The purpose of the procedure is to detect genetic mutations in the RUNX1 gene that could contribute to conditions like acute myeloid leukemia and familial platelet disorder with associated myeloid malignancy. By identifying these genetic changes, doctors can better understand the patient's condition and tailor treatment plans accordingly.
Indications
This analysis is especially warranted in patients with:
- Suspicious symptoms of acute myeloid leukemia.
- A family history of platelet disorders or malignancies.
- Abnormal blood test results that suggest a myeloid disorder.
Preparation
Patients may not need specific preparations for this genetic test. However, it is important to inform the doctor of any medications and medical history. In some cases, a blood sample or a bone marrow biopsy may be required for analysis.
Procedure Description
A blood sample is usually taken from the patient, from which DNA is extracted. This DNA undergoes targeted sequencing to analyze exons 3-8 of the RUNX1 gene. The sequencing process involves advanced laboratory techniques and specialized equipment to identify any mutations within these exons.
Duration
The blood draw itself takes only a few minutes. The entire process, including DNA extraction, sequencing, and analysis, may take a few weeks, depending on the laboratory.
Setting
The initial blood draw is typically performed in a hospital or outpatient clinic. The DNA analysis and sequencing are conducted in a specialized laboratory.
Personnel
- Phlebotomist or nurse for the blood draw.
- Laboratory technicians and geneticists for DNA analysis.
- Doctors or genetic counselors to interpret the results.
Risks and Complications
- Common risks include minor discomfort or bruising at the blood draw site.
- Rare risks may involve an infection at the puncture site.
- There are no significant risks associated with the actual genetic analysis.
Benefits
- Accurate identification of RUNX1 gene mutations.
- Improved understanding of the patient’s condition.
- Personalized treatment plans can be developed based on genetic findings.
- Potential for early diagnosis and intervention.
Recovery
- Patients can resume normal activities immediately after the blood draw.
- No physical recovery is needed from the genetic analysis itself.
- Follow-up appointments may be scheduled to discuss the results and possible treatment options.
Alternatives
- Other genetic analyses looking at different genes or broader panels may also be informative.
- Traditional diagnostic methods such as bone marrow biopsies, complete blood counts, or imaging studies can be used but may not provide the same level of genetic insight.
Patient Experience
Patients may feel a brief pinch during the blood draw but generally experience minimal discomfort. The main waiting period is for the genetic results. It's important for patients to discuss any concerns or questions with their healthcare provider, as well as to understand the potential implications of the test results.